Results 31 to 40 of about 32,855 (128)

Redox Regulation and Oxidative Stress in Health and Disease: Mechanisms and Therapeutic Targeting

MedComm – Future Medicine, Volume 5, Issue 2, June 2026.
Reactive species serve crucial roles which are tightly regulated in both physiological as well as disease states. At physiological levels, these species are integral to redox signaling, while uncontrolled redox promotes disease pathology. This review examines the dysregulation of these processes.
Mohammad Hossein Azadi, Azadeh Niknejad, Elaheh Amini   +2 more
wiley   +1 more source

Early adversity and the comorbidity between metabolic disease and psychopathology

The Journal of Physiology, Volume 604, Issue 11, Page 4338-4377, 1 June 2026.
Abstract figure legend Hierarchical diagram representing the interplay between the genetic background and early life adversities and its effect on multiple physiological processes that ultimately impact on the risk for the comorbdity between psychopathology and cardiometabolic disorders.
Ameyalli Gómez‐Ilescas, Patricia Pelufo Silveira   +1 more
wiley   +1 more source

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Drug Discoveries & Therapeutics
Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder caused by tafazzin mutations that impair cardiolipin remodeling, leading to mitochondrial dysfunction and symptoms such as cardiomyopathy, myopathy, and neutropenia.
Chenru Zhao, Xuemei Zhuang, Jianjun Gao
semanticscholar   +1 more source

Cellular ATP levels alone do not reliably reflect overall mitochondrial bioenergetics or mitochondrial dysfunction in Barth syndrome

Journal of Translational Genetics and Genomics
This review critically examines the question posed by Brault JF, Simon J, and Conway SJ in Journal of Translational Genetics and Genomics earlier this year: “What can ATP content tell us about Barth syndrome muscle phenotypes?”.
Patrice X. Petit
semanticscholar   +1 more source

Barth syndrome

Definitions, 2019
Barth syndrome (BT HS) is a rare, genetic disorder of lipid metabolism that primarily affects males. It is caused by a mutation in the tafazzin gene (T AZ, also called G4.5) which leads to decreased production of an enzyme required to produce cardiolipin.
P. Roxo-Junior, I. Mina
semanticscholar   +1 more source

Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service

JMIR Research Protocols, 2020
Background Barth syndrome is a rare, life-threatening, X-linked recessive genetic disease that predominantly affects young males and is caused by abnormal mitochondrial lipid metabolism.
L. Dabner, Guido E Pieles, C. Steward, Julian P Hamilton-Shield, A. Ness, C. Rogers, C. Bucciarelli-Ducci, R. Greenwood, L. Ellis, K. Sheehan, B. Reeves   +10 more
semanticscholar   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

The diagnostic odyssey, clinical burden, and natural history of Barth syndrome: an analysis of patient registry data

Journal of Translational Genetics and Genomics
Aim: Barth syndrome (BTHS; OMIM 302060) is an ultra-rare, complex, multi-system X-linked disorder that arises from pathogenic mutations in the gene TAFAZZIN .
A. Kenneson, Yonglin Huang, Erik Lontok, Lindsay Marjoram   +3 more
semanticscholar   +1 more source

Vector‐borne diseases‐knowledge maps

EFSA Journal, Volume 24, Issue 5, May 2026.
Abstract This scientific report provides a structured overview of the main characteristics of 25 selected vector‐borne diseases (VBDs) of potential relevance for the EU, including 12 diseases listed under the Animal Health Law (AHL) and 13 non‐listed diseases.
European Food Safety Authority (EFSA), Sofie Dhollander, Ieva Baltusyte, Fabio Bigoni, Alessandro Broglia, Jordi Figuerola, Hans‐Hermann Thulke, Miguel Angel Chueca Miranda   +7 more
wiley   +1 more source